ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

PYC Physiomics Plc

1.25
0.00 (0.00%)
10 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Physiomics Plc LSE:PYC London Ordinary Share GB00BDR6W943 ORD 0.4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1.25 1.10 1.40 1.25 1.25 1.25 592,472 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 597k -477k -0.0035 -3.57 1.69M
Physiomics Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker PYC. The last closing price for Physiomics was 1.25p. Over the last year, Physiomics shares have traded in a share price range of 0.925p to 3.15p.

Physiomics currently has 135,472,478 shares in issue. The market capitalisation of Physiomics is £1.69 million. Physiomics has a price to earnings ratio (PE ratio) of -3.57.

Physiomics Share Discussion Threads

Showing 25126 to 25144 of 30150 messages
Chat Pages: Latest  1014  1013  1012  1011  1010  1009  1008  1007  1006  1005  1004  1003  Older
DateSubjectAuthorDiscuss
23/7/2020
08:35
Yes your right seen it coming 4 or 5p soon
datait
23/7/2020
08:35
Will move up again soonNews will be out soon typical mm's scaring a few ppl to sell
stoop
23/7/2020
08:34
Early stages will take years to get a contract then someone else will be doing the same ?????
datait
23/7/2020
08:33
you seem to be trapped on this thread, that's for sure
bountyhunter
23/7/2020
08:32
Timbrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr
datait
23/7/2020
08:31
Trapped for years to come
datait
23/7/2020
08:30
How low can you go how low can you go all the way to the floor mugs piled in ffs greed
datait
23/7/2020
08:28
This will fall further yet no news for at least 3 weeks
datait
23/7/2020
08:26
Fib retracements on a penny stock? lol
hodhasharon
23/7/2020
08:26
5p coming will hover over it hehehehehe
datait
23/7/2020
08:20
No reason for stock to go further down.. as I explained we already did the classic 61.8% fib retracement yesterday...people selling today after yesterday's retracement will regret
montynj
23/7/2020
08:16
From rns seems project will be around 120k to 200k max ,but this will be good step forward .sp may go down today but it's worth long term holding Dyor
tmmalik
23/7/2020
08:12
The contract with large pharma hasn't disappeared....other contracts still to come...mkt cap of this co still far too low relative to peer group
montynj
23/7/2020
08:08
This is brutal
r9505571
23/7/2020
08:07
A 61.8% fib retracement of rally from 16th July is 10.25p so we have retraced enough now...stock should find a new support around here
montynj
22/7/2020
19:21
For those new to Physiomics

The upcoming 'new Large Pharma' deal isn't the real story here. Even though it could spark a 'domino effect' with over 50+ potential clients talking to PYC [Domino effect might be pushing it with slow moving Big Pharma :-p ]

Real story is in Personalised Oncology Precision Medicine where Physiomics' peers include companies like Tempus a $5 Billion start up !

The coming landgrab phase in growth of that market will IMO see Physiomics valued at hundreds of millions i.e. multiples of 100p as peers understand its unique specialist history in developing Virtual Tumour cancer model for years with some of the best partners around ICR, CRUK, Oxford Uni, Oxford NHS etc etc

the stigologist
22/7/2020
18:07
Today Physiomics tweeted about the 'Exciting news' from their 'historical client Cyclacel'



Now this news is definitely exciting ! (Cyclacel and ICR press released the news on July 13th)

What Cyclacel and the renowned ICR (Institute for Cancer Research) are claiming is that they have a EFFECTIVE new PATHWAY to potentially fight Cancer via CDK Inhibition

“These exciting new findings revealing fadraciclib’s chemical structure and describing its relevant anti-cancer properties, reflect the highly productive collaboration of ICR with Cyclacel to discover and develop innovative cancer treatments,” said Professor Paul Workman, FMedSci, FRS, study co-author and Chief Executive and President, The Institute of Cancer Research, London, UK. “As a potent and selective inhibitor of CDK2 and CDK9, we believe our cumulative findings to-date support fadraciclib’s ability to address key cancer pathways in solid tumors and leukaemias, indicating its potential as a new targeted anti-cancer therapy.”

Why is this significant for Physiomics ?

Physiomics have a long history of working with both Cyclacel and the ICR on CDK Inhibitors

Several resources on Physiomics website attest to that work

So one potential area of interest for Physiomics is that other Pharmas/Biotechs who now want to model either their own CDK pathway drugs or use their existing drugs in combination with CDK Inhibitors may want to come to Physiomics to assist in Modelling and Simulation of those drugs and any future Clinical Trial

BUT could there be a second potential area Physiomics benefit from ? Namely from any milestones or royalties from success of Cyclacel drugs based on their work together ?

the stigologist
22/7/2020
17:20
Bones echoing Stigs comment GREAT POST. Nothing has changed the company is still way undervalued BUT we did see how quickly this can rise from 10p. Long term holders will not be put off by daily volatility. Lets wait for the next announcement that will surely follow.
ant15
22/7/2020
16:58
Is that it then?
divmad
Chat Pages: Latest  1014  1013  1012  1011  1010  1009  1008  1007  1006  1005  1004  1003  Older

Your Recent History

Delayed Upgrade Clock